<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Sarcoma</journal-id><journal-title>Sarcoma</journal-title><issn pub-type="ppub">1357-714X</issn><issn pub-type="epub">1369-1643</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18521432</article-id><article-id pub-id-type="pmc">2408358</article-id>
            <article-id pub-id-type="pii">S1357714X00000062</article-id>
            <article-id pub-id-type="doi">10.1155/S1357714X00000062</article-id>
      <article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced
Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and
Bone Sarcoma Group</article-title></title-group><contrib-group>
            <contrib contrib-type="author" corresp="yes"><name><surname>Nielsen</surname><given-names>Ole S.</given-names></name><address><email>osn@oncology.dk.</email></address><xref ref-type="aff" rid="aff1">1</xref></contrib>
            <contrib contrib-type="author"><name><surname>Dombernowsky</surname><given-names>Per</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib>
            <contrib contrib-type="author"><name><surname>Mouridsen</surname><given-names>Henning</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib>
            <contrib contrib-type="author"><name><surname>Daugaard</surname><given-names>S&#x000f8;ren</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib>
            <contrib contrib-type="author"><name><surname>Van Glabbeke</surname><given-names>Martine</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib>
            <contrib contrib-type="author"><name><surname>Kirkpatrick</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib>
            <contrib contrib-type="author"><name><surname>Verweij</surname><given-names>Jaap</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib>
      </contrib-group>
            <aff id="aff1"><label>1</label>
                <addr-line>Centre for Bone and Soft Tissue Sarcomas</addr-line>
                <addr-line>Aarhus University Hospital</addr-line>
                <addr-line>Aarhus</addr-line>
                <country>Denmark</country>
            </aff>
            <aff id="aff2"><label>2</label>
                <addr-line>Department of Oncology</addr-line>
                <addr-line>Copenhagen University Hospital</addr-line>
                <addr-line>Herlev</addr-line>
                <country>Denmark</country>
            </aff>
            <aff id="aff3"><label>3</label>
                <addr-line>The Finsen Center</addr-line>
                <addr-line>Rigshospitalet</addr-line>
                <addr-line>Copenhagen</addr-line>
                <country>Denmark</country>
            </aff>
            <aff id="aff4"><label>4</label>
                <addr-line>The Laboratory Center</addr-line>
                <addr-line>Rigshospitalet</addr-line>
                <addr-line>Copenhagen</addr-line>
                <country>Denmark</country>
            </aff>
            <aff id="aff5"><label>5</label>
                <addr-line>EORTC Data Centre</addr-line>
                <addr-line>Brussels</addr-line>
                <addr-line>Belgium and Department of Medical Oncology</addr-line>
                <country>The Netherlands</country>
            </aff>
            <aff id="aff6"><label>6</label>
                <addr-line>Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital</addr-line>
                <addr-line>Rotterdam</addr-line>
                <country>The Netherlands</country>
            </aff>
        <pub-date pub-type="ppub"><month>3</month><year>2000</year></pub-date><volume>4</volume><issue>1-2</issue><fpage>31</fpage><lpage>35</lpage><permissions><copyright-statement>Copyright &#x000a9; 2000 Hindawi Publishing Corporation.</copyright-statement><copyright-year>2000</copyright-year><copyright-holder>Hindawi Publishing Corporation</copyright-holder><license license-type="open-access" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract>
            <p><italic>Purpose.</italic> Doxorubicin (dox) still appears to be one of the most active
            drugs in the treatment of soft tissue sarcomas. However, treatment duration is limited due to
            cumulative cardiotoxicity. A number of small studies from single institutions have suggested
            activity of other analogues. In two studies the EORTC STBSG tested whether epirubicin (epi)
            is an alternative to standard dose dox in the treatment of chemonaive patients with advanced
            soft tissue sarcoma. The present report gives the final results of these studies.</p>
            <p><italic>Patients/Methods.</italic> In the first study 210 patients were randomized to
            receive either dox or epi both at a dose of 75 mg/m<sup>2</sup> given as bolus injection at 3-week
            intervals. In the second study 334 patients were randomized to dox 75 mg/m<sup>2</sup>,
            epi 150 mg/m<sup>2</sup> or epi 50 mg/m<sup>2</sup> days 1&#x02013;3, all given as bolus injection at 3-week intervals.</p>
            <p><italic>Results.</italic> In the first study no differences in median survival and duration
            of response were found. Of 167 evaluable patients the response rate was slightly in favour of
            dox (23% vs 18%) but at the expense of more toxicity.These data could suggest that increasing
            the epi dose may lead to a greater antineoplastic effect with acceptable toxicity. In the second
            study 15% of 314 evaluable patients had an objective tumour response.
            There were no differences between the three groups with regard to response rate,
            progression-free and overall survival, but both dose schedules of epi were more myelotoxic
            than dox.</p>
            <p><italic>Conclusion.</italic> Regardless of schedule and dose, epi is not superior to dox
            in the treatment of patients with advanced soft tissue sarcomas. In addition, the results
            illustrate that the data from small studies of single institutions should always be confirmed
            by large multi-institutional studies before being taken for granted.</p>
        </abstract></article-meta></front></article>


